Lizanne Béïque1, Rosemary Zvonar2. 1. BPharm, PharmD, is a Clinical Pharmacy Specialist for the Antimicrobial Stewardship Program, Pharmacy Department, The Ottawa Hospital, and a Clinical Investigator with the Ottawa Hospital Research Institute, Ottawa, Ontario. 2. BScPhm, ACPR, FCSHP, is currently Antimicrobial Stewardship Program Lead with Public Health Ontario (on leave from her position as Antimicrobial Pharmacy Specialist with the Pharmacy Department, The Ottawa Hospital, Ottawa, Ontario.).
Abstract
BACKGROUND: Many health care institutions are in the process of establishing antimicrobial stewardship programs. Changing the route of administration of antimicrobial agents from intravenous to oral (IV to PO) is a simple, well-recognized intervention that is often part of an antimicrobial stewardship program. However, the attending health care team may have concerns about making this switch. OBJECTIVES: To provide insights into common concerns related to IV to PO conversion, with the aim of helping antimicrobial stewardship teams to address them. DATA SOURCES: Published clinical trials and reviews were identified from a literature search of Ovid MEDLINE with the keywords (step down or switch or conversion or transition or sequential) and (antibiotics or antibacterial agents or antimicrobial or anti-infective agents). DATA SYNTHESIS: The following issues are addressed in this review: benefits of the oral route, serum concentrations yielded by the oral formulation, source of pharmacokinetic data, clinical outcomes, provision of care in the intensive care unit, fear of therapeutic failure, and administration of antimicrobials via feeding tube. CONCLUSIONS: When considering a change to oral therapy, it is important to have a thorough understanding of key aspects of the antimicrobial agent, the patient, and the disease being treated. The antimicrobial stewardship team has an important role in facilitating IV to PO conversion, educating prescribers, and addressing any concerns or reservations that may interfere with timely transition from IV to PO administration.
BACKGROUND: Many health care institutions are in the process of establishing antimicrobial stewardship programs. Changing the route of administration of antimicrobial agents from intravenous to oral (IV to PO) is a simple, well-recognized intervention that is often part of an antimicrobial stewardship program. However, the attending health care team may have concerns about making this switch. OBJECTIVES: To provide insights into common concerns related to IV to PO conversion, with the aim of helping antimicrobial stewardship teams to address them. DATA SOURCES: Published clinical trials and reviews were identified from a literature search of Ovid MEDLINE with the keywords (step down or switch or conversion or transition or sequential) and (antibiotics or antibacterial agents or antimicrobial or anti-infective agents). DATA SYNTHESIS: The following issues are addressed in this review: benefits of the oral route, serum concentrations yielded by the oral formulation, source of pharmacokinetic data, clinical outcomes, provision of care in the intensive care unit, fear of therapeutic failure, and administration of antimicrobials via feeding tube. CONCLUSIONS: When considering a change to oral therapy, it is important to have a thorough understanding of key aspects of the antimicrobial agent, the patient, and the disease being treated. The antimicrobial stewardship team has an important role in facilitating IV to PO conversion, educating prescribers, and addressing any concerns or reservations that may interfere with timely transition from IV to PO administration.
Entities:
Keywords:
IV to PO transition; antimicrobial stewardship programs; antimicrobials; intravenous therapy; oral therapy; step-down
Authors: Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Mohammed Desai; Bryony Dean Franklin; Alison H Holmes; Sarah Trust; Mike Richards; Ann Jacklin; Kathleen B Bamford Journal: BMC Infect Dis Date: 2006-06-08 Impact factor: 3.090
Authors: Baharak Babouee Flury; Luigia Elzi; Marko Kolbe; Reno Frei; Maja Weisser; Stefan Schären; Andreas F Widmer; Manuel Battegay Journal: BMC Infect Dis Date: 2014-04-27 Impact factor: 3.090
Authors: I Russel Lee; Steven Y C Tong; Joshua S Davis; David L Paterson; Sharifah F Syed-Omar; Kwong Ran Peck; Doo Ryeon Chung; Graham S Cooke; Eshele Anak Libau; Siti-Nabilah B A Rahman; Mihir P Gandhi; Luming Shi; Shuwei Zheng; Jenna Chaung; Seow Yen Tan; Shirin Kalimuddin; Sophia Archuleta; David C Lye Journal: Trials Date: 2022-07-19 Impact factor: 2.728
Authors: Pranita D Tamma; Anna T Conley; Sara E Cosgrove; Anthony D Harris; Ebbing Lautenbach; Joe Amoah; Edina Avdic; Pam Tolomeo; Jacqueleen Wise; Sonia Subudhi; Jennifer H Han Journal: JAMA Intern Med Date: 2019-03-01 Impact factor: 21.873
Authors: Charlotte Quintens; Marie Coenen; Peter Declercq; Minne Casteels; Willy E Peetermans; Isabel Spriet Journal: BMJ Open Date: 2022-04-08 Impact factor: 2.692